The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B

• DOI: 10.18553/jmcp.2024.30.8.868
• Publication Date: 2024-08-01T16:32:55Z
• Authors: Jyotirmoy Sarker; Jeffrey A. Tice; David M. Rind; Steven D. Pearson; Surrey M. Walton
• Keywords: Impact factor

This viewpoint discusses cost-effectiveness estimates for EtranaDez, a gene therapy hemophilia B, using the Institute Clinical and Economic Review's (ICER) framework single short-term therapies (SSTs). EtranaDez offers long-term benefits from administration, in contrast to high costs frequent dosing required by current factor IX prophylaxis. However, projected gains health are small relative cost implications of therapy, consequently, how offsets associated with counted has substantial impact on assessing its cost-effectiveness. Strategies used ICER SST include 50/50 cost-sharing model between care system manufacturer cap $150,000 annually offsets. Results standard full cost-offset analysis as reported depicted dominant savings compared while considering framework, particularly annual scenario, was significantly reduced. The incremental ratio varied notably these scenarios, challenging conventional perception value care. These scenarios highlight potential help curtail inefficient spending. In cases which existing treatment is exceedingly high, application such frameworks would improve efficiency resource allocation, fostering balance incentives innovation economic sustainability managed systems.